Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | PRKCA | P17252 | 2/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.33 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | HRH2 | P25021 | 4/20 | 0.32 |
| ▸ | HRH1 | P35367 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 4/20 | 0.31 |
| ▸ | WNT3A | P56704 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138949 | 0.82 | TNFRSF1A (0.37) | CTNNB1L3MBTL1ABCB11CYP3A4ADRA2B | |
| SCHEMBL6138864 | 0.79 | L3MBTL1 (0.38) | CTNNB1L3MBTL1ABCB11CYP3A4ADRA2B | |
| SCHEMBL6138900 | 0.75 | HDAC1 (0.49) | L3MBTL1ABCB11CYP3A4ADRA2BOPRD1 | |
| SCHEMBL6138774 | 0.70 | KCNMA1 (0.50) | MAPTLMNA | |
| SCHEMBL6138941 | 0.69 | HAO1 (0.44) | CTNNB1L3MBTL1ABCB11CYP3A4ADRA2B | |
| SCHEMBL13854938 | 0.68 | L3MBTL1 (0.49) | L3MBTL1 | |
| SCHEMBL6138955 | 0.67 | MAPT (0.49) | L3MBTL1MAPT | |
| SCHEMBL9903196 | 0.67 | DGKA (0.57) | ABCB11CYP3A4ADRA2BOPRD1SCN5A | |
| SCHEMBL2304415 | 0.67 | DGKA (0.57) | ABCB11CYP3A4ADRA2BOPRD1SCN5A | |
| SCHEMBL17998754 | 0.67 | DGKA (0.57) | ABCB11CYP3A4ADRA2BOPRD1SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1215203-B1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20040214896-A1 | Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-10-28 | — | — | US | disclosed |
| US-6770644-B1 | Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| EP-1215203-A1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214896-A1 | Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient | HIF1AN, IL6, PYGM | CTNNB1 2010/4885L3MBTL1 1777/4885PRKCA 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.